Gareth Sheridan, CEO of Nutriband Inc. (NASDAQ: NTRB), has been selected as a finalist in the Established category of the 2025 EY Entrepreneur of the Year Awards. The recognition highlights Sheridan’s leadership in transforming Nutriband from a startup to a publicly traded life sciences company focused on innovative pharmaceutical solutions.
Out of 24 companies generating more than €1 billion in annual revenue, Sheridan was among 27 Irish entrepreneurs honored for their exceptional leadership and impact. The prestigious award acknowledges his strategic vision in developing advanced transdermal drug delivery technologies.
Nutriband’s primary focus is developing transdermal pharmaceutical products, with its lead product AVERSA™ designed to prevent misuse and abuse of opioid patches. The AVERSA technology represents a critical advancement in addressing potential drug abuse risks by incorporating abuse-deterrent mechanisms into transdermal patches.
As a finalist, Sheridan will participate in a CEO retreat in Japan and compete for the overall Entrepreneur of the Year title. The final award will be presented at a gala event in November, providing a significant platform to showcase Nutriband’s innovative approach to pharmaceutical product development.
The EY Entrepreneur of the Year Award recognizes outstanding entrepreneurs who demonstrate excellence, success, and transformative leadership in their respective industries. Sheridan’s nomination underscores Nutriband’s commitment to developing safer pharmaceutical technologies that can potentially mitigate the risks associated with pain management medications.
This news story relied on a press release distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Nutriband CEO Gareth Sheridan Named EY Entrepreneur of the Year 2025 Finalist.